PATENT CLAIM ANALYSIS

Application Number: 16110566
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "134100"]

Abstract:
SIRPabodies comprise an immunoglobulin variable region, which may specifically bind a tumor antigen, viral antigen, etc., fused to a sequence comprising a binding domain of SIRPα. The binding domain of SIRPα comprises at least the N-terminal Ig-like domain of SIRPα, and may further comprise additional SIRPα sequences. The SIRPabodies find use in therapeutic methods that benefit from the combined activity of blocking CD47 activity, and antibody targeting, e.g. in the treatment of cancer, etc. In some specific embodiments, the SIRPabody comprises anti-CD20 activity and a SIRPα binding domain; anti-CD99 and a SIRPα binding domain; or anti-TIM3 activity and a SIRPα binding domain.

Claim (Index 16):
The method of  claim 13 , wherein the cancer is acute myeloid leukemia.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 96.0
- Lexical Diversity: 1.84375
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15502475', '15122560', '14371370', '15660510', '15473206']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8028672963138959
- 35 USC 102 Novelty (BERT): 0.6139258497424098
- Combined Prediction Score: 0.7839731516567472
- Mean Citation Score: 483.412824
- Max Citation Score: 710.2159
- Similarity Product: 470.9951341985703

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test